Form 8-K · Current Report · Filed 2026-02-02
Revvity, Inc. Announces Financial Results for Q4 and Full Year 2025
Revvity, Inc. reported its financial results for the fourth quarter and full year of 2025, showing revenue of $772 million and $2.86 billion respectively. The company reported GAAP earnings per share (EPS) of $0.87 for Q4 and $2.07 for the full year, with adjusted EPS from continuing operations at $1.70 and $5.06 respectively. The company also provided guidance for 2026, forecasting total revenue between $2.96 billion and $2.99 billion with organic growth of 2-3% and adjusted EPS of $5.35-$5.45.
- Filer
- Revvity Inc. RVTY · NYSE
- Filed
- Accession
- 0000031791-26-000007
- CIK
- 0000031791
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$108.80
Next session
-7.0%
Since filing
+34.9%
Latest close
$146.73
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVTY reporting the same item, with the next session's move:
About Revvity Inc.
Revvity Inc. is a health science tools and diagnostics company that provides end-to-end solutions for research, development, testing, and clinical use. The company operates through two main segments: Life Sciences and Diagnostics, serving customers across pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations. Its portfolio includes reagents, consumables, assays, instruments, software, and specialized services that support workflows from discovery through diagnosis. Revvity focuses on areas such as translational multi-omics, biomarker identification, imaging, screening, detection, informatics, reproductive health, immunodiagnostics, and genomic testing. It also supports applications in rare disease testing, newborn screening, hereditary cancer, and broader clinical laboratory services. Based in Waltham, Massachusetts, Revvity plays an important role in the healthcare and life sciences ecosystem by helping researchers, clinicians, and laboratories generate and analyze data across a wide range of scientific and diagnostic applications.
Never miss another RVTY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.